Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXUROC Bladder Target
2026-525808-94-00Phase 2Authorised
- Sponsor
- Capital Region of Denmark
- Start
- Jul 2026
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of LP-184 in transitional cell carcinoma (TCC), sponsored by Capital Region of Denmark. Primary endpoints: Dose-Limiting Toxicity, Recommended Phase 2 Dose and 1 more. Planned start Jul 2026; status: authorised.
02
Drugs
LP-184
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2026-525808-94-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525808-94-00.